Comprehensive genomic profiling testing in Japanese castration-resistant prostate cancer patients: results of a single-center retrospective cohort study

被引：1

作者：

Fukushima, Takafumi ^{[1
]}

Goto, Keisuke ^{[1
]}

Hayashi, Tetsutaro ^{[1
]}

Ikeda, Kenichiro ^{[1
]}

Hatayama, Tomoya ^{[1
]}

Yamanaka, Ryoken ^{[1
]}

Iwane, Kyosuke ^{[1
]}

Tasaka, Ryo ^{[1
]}

Kohada, Yuki ^{[1
]}

Takemoto, Kenshiro ^{[1
]}

Kobatake, Kohei ^{[1
]}

Goriki, Akihiro ^{[1
]}

Toshida, Asuka ^{[2
]}

Nakahara, Hikaru ^{[2
]}

Motonaga, Masanori ^{[3
]}

Tokumo, Kentaro ^{[4
]}

Fujii, Yasutoshi ^{[4
,5
]}

Hayes, C. Nelson ^{[5
]}

Okamoto, Wataru ^{[6
]}

Kubo, Toshio ^{[7
]}

Matsumoto, Takashi ^{[8
]}

Shiota, Masaki ^{[8
]}

Yamamoto, Noboru ^{[9
]}

Urabe, Yuji ^{[10
]}

Hiyama, Eiso ^{[11
,12
]}

Arihiro, Koji ^{[13
]}

Hinoi, Takao ^{[2
]}

Hinata, Nobuyuki ^{[1
]}

机构：

[1] Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Urol, 1-2-3 Kasumi,Minamiku, Hiroshima 7348551, Japan

[2] Hiroshima Univ Hosp, Genom Med Ctr, Dept Clin & Mol Genet, Hiroshima, Japan

[3] Hiroshima Univ Hosp, Dept Pharmaceut Serv, Hiroshima, Japan

[4] Hiroshima Univ Hosp, Dept Clin Oncol, Hiroshima, Japan

[5] Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Gastroenterol, Hiroshima, Japan

[6] Hiroshima Univ Hosp, Canc Treatment Ctr, Hiroshima, Japan

[7] OkayamaUnivers Hosp, Ctr Clin Oncol, Okayama, Japan

[8] Kyushu Univ, Grad Sch Med Sci, Dept Urol, Fukuoka, Japan

[9] Natl Canc Ctr, Dept Expt Therapeut, Tokyo, Japan

[10] Hiroshima Univ Hosp, Dept Gastrointestinal Endoscopy & Med, Hiroshima, Japan

[11] Hiroshima Univ Hosp, Dept Pediat Surg, Hiroshima, Japan

[12] Hiroshima Univ, Nat Sci Ctr Basic Res & Dev, Hiroshima, Japan

[13] Hiroshima Univ Hosp, Dept AnatomicalPathol, Hiroshima, Japan

来源：

JAPANESE JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 54卷 / 02期

关键词：

castration-resistant prostate cancer; comprehensive genome profiling testing; next-generation sequencing; CDK12; chemotherapy; POSITIVE SOLID TUMORS; INCREASED SURVIVAL; DOCETAXEL; PREDNISOLONE; MITOXANTRONE; ABIRATERONE;

D O I：

10.1093/jjco/hyad148

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Objective Comprehensive genomic profiling testing using a hybrid-capture next-generation sequencing is commonly used in clinical practice to employ precision medicine in cancer treatment worldwide. In this study, we aimed to analyze the profiles obtained using comprehensive genomic profiling testing that was performed in Japanese castration-resistant prostate cancer patients and to discuss the genetic findings in a real-world setting.Methods A total of 60 cases and 57 castration-resistant prostate cancer patients underwent comprehensive genomic profiling testing between 1 January 2021 and 31 December 2022. Four types of comprehensive genomic profiling testing were selected, and clinically significant cancer-specific gene alterations were identified.Results The median age of patients was 74 years, and the median prostate-specific antigen value at the time of submission was 18.6 ng/ml. Fifty-seven (95%) of 60 cases were metastatic castration-resistant prostate cancers, and 3 cases (5%) were non-metastatic. Among all genetic alterations, androgen-receptor alteration was the most frequently detected in 17 cases (28.3%), followed by 15 cases of TP53 (25.0%), 14 cases of CDK12 (23.3%), 10 cases of phosphatase and tensin homolog (16.7%) and 9 cases of ATM (15.0%) mutations. A total of 13 patients (21.7%) received systemic therapy according to the comprehensive genomic profiling testing results. Overall, the survival rate was significantly greater in the group treated through systemic therapy based on comprehensive genomic profiling testing compared with the group without new therapeutic treatment (P = 0.041).Conclusions Comprehensive genomic profiling testing is recommended in castration-resistant prostate cancer patients identified as resistant to standard therapy as this can provide a new therapeutic option. Comprehensive genomic profiling testing is useful for the selection of treatment for Japanese patients with castration-resistant prostate cancer.

引用

页码：175 / 181

页数：7

共 50 条

[31] A phase 1 multiple-dose study of orteronel in Japanese patients with castration-resistant prostate cancer
Suzuki, Kazuhiro
Ozono, Seiichiro
Yamaguchi, Akito
Koike, Hidekazu
Matsui, Hiroshi
Nagata, Masao
Takubo, Takatoshi
Miyashita, Kana
Matsushima, Takafumi
Akaza, Hideyuki
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 75 (02) : 373 - 380
[32] Reduced-dose docetaxel for castration-resistant prostate cancer has no inferior impact on overall survival in Japanese patients
Kita, Yuki
Shimizu, Yosuke
Inoue, Takahiro
Kamba, Tomomi
Yoshimura, Koji
Ogawa, Osamu
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2013, 18 (04) : 718 - 723
[33] Docetaxel followed by abiraterone in metastatic castration-resistant prostate cancer: efficacy and predictive parameters in a large single center cohort
Thomas Höfner
Sonia Vallet
Boris A. Hadaschik
Sascha Pahernik
Stefan Duensing
Markus Hohenfellner
Dirk Jäger
Carsten Grüllich
World Journal of Urology, 2015, 33 : 833 - 839
[34] A Retrospective, Canadian Multi-Center Study Examining the Impact of Prior Response to Abiraterone Acetate on Efficacy of Docetaxel in Metastatic Castration-Resistant Prostate Cancer
Azad, Arun A.
Leibowitz-Amit, Raya
Eigl, Bernhard J.
Lester, Renee
Wells, J. Connor
Murray, R. Nevin
Kollmannsberger, Christian
Heng, Daniel Y. C.
Joshua, Anthony M.
Chi, Kim N.
PROSTATE, 2014, 74 (15): : 1544 - 1550
[35] Feasibility of classical secondary hormonal therapies prior to docetaxel therapy in Japanese patients with castration-resistant prostate cancer: Multicenter retrospective study
Kandori, Shuya
Yoshino, Takayuki
Tsutsumi, Masakazu
Yamauchi, Atsushi
Ohtani, Mikinobu
Fukuhara, Yoshiharu
Miyanaga, Naoto
Miyazaki, Jun
Nishiyama, Hiroyuki
Shimazui, Toru
PROSTATE INTERNATIONAL, 2016, 4 (04) : 140 - 144
[36] 225Ac-Prostate-Specific Membrane Antigen Therapy for Castration-Resistant Prostate Cancer A Single-Center Experience
Sanli, Yasemin
Kuyumcu, Serkan
Simsek, Duygu Has
Buyukkaya, Fikret
Civan, Caner
Isik, Emine Goknur
Ozkan, Zeynep Gozde
Basaran, Mert
Sanli, Oner
CLINICAL NUCLEAR MEDICINE, 2021, 46 (12) : 943 - 951
[37] Clinical application of comprehensive genomic profiling panel to thoracic malignancies: A single-center retrospective study
Kunimasa, Kei
Sugimoto, Naotoshi
Kawamura, Takahisa
Yamasaki, Tomoyuki
Honma, Keiichiro
Nagata, Shigenori
Kukita, Yoji
Fujisawa, Fumie
Inoue, Tazuko
Yamaguchi, Yuko
Kitasaka, Mitsuko
Wakamatsu, Toru
Yamai, Takuo
Yamamoto, Sachiko
Hayashi, Takuji
Inoue, Takako
Tamiya, Motohiro
Imamura, Fumio
Nishimura, Kazuo
Nishino, Kazumi
THORACIC CANCER, 2022, 13 (21) : 2970 - 2977
[38] Efficacy of Novel Hormone Agents in the Treatment of Metastatic Castration-resistant Prostate Cancer: A Real-world Retrospective Study
LI, Jian-ri
Wang, Shian-shiang
Chen, Chuan-shu
Yang, Cheng-kuang
Lu, K. E. V. I. N.
Cheng, Chen-Li
Hung, Sheng-Chun
Chen, Shu-Yen
Hsu, Chiann Yi
Chiu, Kun-Yuan
ANTICANCER RESEARCH, 2022, 42 (10) : 4857 - 4866
[39] Lenalidomide Monotherapy in Chemotherapy-Naive, Castration-Resistant Prostate Cancer Patients: Final Results of a Phase II Study
Nabhan, Chadi
Patel, Anand
Villines, Dana
Tolzien, Kathy
Kelby, Susan K.
Lestingi, Timothy M.
CLINICAL GENITOURINARY CANCER, 2014, 12 (01) : 27 - 32
[40] Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer
Matsubara, Nobuaki
Nagamori, Satsohi
Wakumoto, Yoshiaki
Uemura, Hirotsugu
Kimura, Go
Yokomizo, Akira
Kikukawa, Hiroaki
Mizokami, Atsushi
Kosaka, Takeo
Masumori, Naoya
Kawasaki, Yoshihide
Yonese, Junji
Nasu, Yasutomo
Fukasawa, Satoshi
Sugiyama, Takayuki
Kinuya, Seigo
Hosono, Makoto
Yamaguchi, Iku
Tsutsui, Hirokazu
Uemura, Hiroji
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2018, 23 (01) : 173 - 180

← 1 2 3 4 5 →